Qulipta atogepant korea approval?

See the DrugPatentWatch profile for Qulipta

AbbVie's Qulipta (atogepant) received approval in South Korea for the preventive treatment of episodic migraine [1]. This marks a significant expansion for the drug's availability in the Asian market.

What is Qulipta approved for?

Qulipta is approved to prevent episodic migraine in adults [1]. Episodic migraine is characterized by a certain frequency of migraine headaches occurring on a limited number of days per month.

When was Qulipta approved in South Korea?

Qulipta was approved in South Korea in October 2023 [1].

What is atogepant?

Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist [1]. CGRP is a molecule that plays a role in migraine pain. By blocking the CGRP receptor, atogepant is thought to help prevent migraine headaches.

Where else is Qulipta available?

Qulipta is also approved and available in the United States and the European Union [1]. Its approval in South Korea expands its global reach.

Who developed Qulipta?

Qulipta was developed by AbbVie [1]. AbbVie is a biopharmaceutical company with a focus on developing and marketing treatments for a range of serious health conditions.